| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
For anti-cancer treatment, biologically optimal dosing in addition to state of art supportive care in order to aim for best drug efficacy is very important.
We have conducted several clinical trial aiming for better management for chemotherapy-induced nausea and vomiting, molecular targeted drug-related skin rash, 5HT3-induced constipation and published them at the major scientific conference or journal.
We also conducted clinical trial to find out biologially optimal dosing for anti-anti-neoplastics, such as decetaxel, afatinib irinotecan and TS-1. We also published them at the major scientific conference or journal.
|
